GPCM
GBT

Granite Point Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Granite Point Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-30,000
Closed -$1.36M – 148
2018
Q2 		$1.36M Buy
30,000
+9,700
+48% +$442K 0.12% 60
2018
Q1 		$980K Sell
20,300
-4,700
-19% -$262K 0.09% 60
2017
Q4 		$984K Buy
+25,000
New +$934K 0.1% 57

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Granite Point Capital Management's GBT Position: Q3 2018 in Review

Granite Point Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2018, closing a stake of 30,000 shares — an estimated $1.36M sold.

Granite Point Capital Management first reported a position in GBT in Q4 2017 and held it in 3 quarters. The position peaked at $1.36M in Q2 2018. 184 funds tracked by Wall St. Rank hold GBT as of Q3 2018.

  • Granite Point Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Granite Point Capital Management sold 30,000 Global Blood Therapeutics, Inc. shares in Q3 2018, an estimated $1.36M.
  • Granite Point Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 3 quarters.
  • Granite Point Capital Management's Global Blood Therapeutics, Inc. position peaked at $1.36M in Q2 2018.
  • 184 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2018.

Based on Granite Point Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.